Slootbeek PHJ, Duizer ML, van der Doelen MJ, et al. - Researchers conducted a retrospective assessment of 71 patients on platinum use in the Netherlands. Thirty individuals were grouped based on the presence of pathogenic aberrations in genes associated with DNA damage repair or aggressive variant prostate cancer for a predefined sub‐analysis of all patients with comprehensive next‐generation sequencing. The data validate that BRCA2 inactivation is correlated with meaningful responses to carboplatin, implying a role for both PARP inhibitors and platinum‐based chemotherapy in pre‐selected metastatic castration‐resistant prostate cancer patients.